{"disease":{"id":"chronic-pouchitis","name":"chronic pouchitis"},"drugs":{"marketed":[{"drug_id":"vedolizumab","indication_name":"Chronic antibioticrefractory ileal pouchitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Entyvio","generic_name":"vedolizumab","company_name":"Takeda","drug_phase":"marketed","molecular_target":"Integrin alpha-4/beta-7","drug_class":"Integrin Receptor Antagonist [EPC]","quality_score":10,"revenue":"7300","mechanism":"Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}